News
Product launch: Pig NGAL ELISA Kit (KIT 044)
August 16 2010
BioPorto’s NGAL test approved for use by leading U.S. reference laboratory
August 12 2010
AACC/Clinical Lab Expo 2010, July 27-29, Anaheim, CA
July 06 2010
IUTOX 2010, July 19-23, Barcelona, Spain
June 30 2010
BioPorto Diagnostics at the ERA-EDTA Congress, Munich, June 25-28
June 14 2010
BioPorto Diagnostics at APCN 2010, June 5-8, Seoul, Korea
May 21 2010
Presentation of The NGAL Test data at the BRS/RA Conference, May 17-20, Manchester, UK
May 14 2010
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
TSIS 2010, March 9-13, Munich, Germany
February 18 2010
ToxExpo, March 7-11, Salt Lake City, Utah
February 16 2010
Product launch: Mouse NGAL ELISA Kit (KIT 042)
July 07 2009 by Ana Belén Enfedaque Buisán
BioPorto Diagnostics has launched an ELISA test for the determination of the acute kidney injury marker NGAL in mice. NGAL determination allows kidney injury to be detected almost as soon as it occurs and not just at the later stage when the consequences of damage have set in with impaired kidney function or actual failure.
Mice are among the most frequently used laboratory animals and often used in early research and development of potential drug treatments and the Mouse NGAL model has previously shown great promise. The Mouse NGAL Kit complements the NGAL product line and serves as an alternative to the rat model when assessing kidney damage as a result of nephrotoxic or ischemic events.
Therefore NGAL measurement in mice could prove to be of considerable value in the preclinical evaluation of new pharmacological products, as it is much cheaper and easier to determine NGAL than to carry out the typical microscopic examination of the kidney itself. BioPorto Diagnostics’ expectations are supported by a rather constant demand for animal NGAL ELISAs since the launch of the first human NGAL ELISA Kit.
The Mouse NGAL test can thus be used early in the development of new treatments for kidney damage, to detect nephrotoxic side effects of new drugs, and for basic science research on kidney injury and kidney diseases.
BioPorto Diagnostics’ expectations are supported by an incipient demand for animal NGAL ELISAs from the pharmaceutical industry and the CROs (Contract Research Organizations) that carry out the majority of the industry’s testing, as well as from large publicly-funded international research institutions.
Click here to go to the NGAL (mouse, neutrophil gelatinase-associated lipocalin) product page
